Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-27T20:54:55.673Z Has data issue: false hasContentIssue false
  • English
  • Français

The Toronto Observational Study of Natalizumab in Multiple Sclerosis

Published online by Cambridge University Press:  02 December 2014

Kristen M. Krysko  and
Paul W. O'Connor
Kristen M. Krysko
Affiliation:
Division of Neurology, St. Michael's Hospital, Toronto, Ontario, Canada
Paul W. O'Connor*
Affiliation:
Division of Neurology, St. Michael's Hospital, Toronto, Ontario, Canada
*
MS Clinic and MS Research, St. Michael’s Hospital, 30 Bond St #3007S, Toronto, Ontario, M5B 1W8, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Natalizumab is indicated for the treatment of relapsing multiple sclerosis (MS) with insufficient response to first-line disease-modifying therapy (DMT). We studied the efficacy of natalizumab for treatment of MS in a single centre observational design.

Methods:

A retrospective observational study of 146 patients [66% female; mean age 37.4; 72% relapsing remitting MS (RRMS), 28% secondary progressive MS (SPMS)] referred for natalizumab treatment at St. Michael's Hospital MS Clinic between 2007 and August 2009. Data included demographic, clinical (Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR)) and patient self-report measures.

Results:

The mean duration of treatment was 20 months in those treated with natalizumab and 97% had received prior DMTs. Eighty-three patients (57%) received at least 12 months of natalizumab treatment. In those who received at least 12 months of treatment, baseline ARR and EDSS were 1.6 and 2.7 in RRMS patients versus 1.0 and 5.4 in SPMS with relapses. The ARR decreased with natalizumab treatment to 0.38 (76% reduction, p<0.001) in RRMS versus 0.32 in SPMS patients (68% reduction, p=0.01). There was a treatment associated 11% reduction in EDSS to 2.4 (p=0.04) in RRMS, but no significant change in SPMS. Eighty-five percent of patients reported improved overall quality of life (QOL) and 62% indicated improved energy.

Conclusions:

There was a major reduction in relapse rate, stabilization in EDSS and improvement in QOL and energy in some patients on natalizumab, all similar to treatment effects in the pivotal trial.

Résumé:

Résumé:Contexte:

Le natalizumab est indique dans le traitement de la sclerose en plaques (SP) remittente qui ne repond pas suffisamment au traitement de fond (TF) de premiere ligne. Nous avons utilise un plan d’etude d’observation dans un seul centre pour etudier l’efficacite du natalizumab pour traiter la SP.

Méthode:

Il s’agit d’une etude d’observation retrospective portant sur 146 patients atteints de SP [72% de SP remittente (SPR) et 28% de SP secondairement progressive (SPSP)], dont 66% etaient des femmes et dont l’age moyen etait de 37,4 ans. Ils avaient ete referes a la clinique de SP de St. Michael's Hospital pour traitement par le natalizumab entre 2007 et aout 2009. Nous avons recueilli les donnees demographiques, le score a l’Expanded Disability Status Scale (EDSS) et le taux annualise de rechute (TAR) et les mesures rapportees par les patients.

Résultats:

La duree moyenne de traitement etait de 20 mois chez les patients traites par le natalizumab et 97% ont recu d’autres TF. Quatre-vingt-trois patients (57%) ont recu le natalizumab pendant au moins 12 mois. Chez ces patients, le TAR et l’EDSS avant traitement etaient de 1,6 et 2,7 respectivement chez les patients atteints de SPR et de 1,0 et 5,4 chez ceux atteints de SPSP qui ont eu des recidives. Le TAR a diminue sous traitement par le natalizumab a 0,38 (diminution de 76%, p < 0,001) chez les patients atteints de SPR et a 0,32 chez ceux atteints de SPSP (diminution de 68%, p = 0,01). Nous avons observe une diminution de 11% du score a l’EDSS associee au traitement, soit 2,4 chez les patients atteints de SPR (p = 0,04). Il n’y a eu aucun changement significatif du score a l’EDS chez ceux atteints de SPSP. Quatre-vingtcinq pour cent des patients ont note une amelioration globale de leur qualite de vie (QV) et 62% ont note un niveau d’energie plus eleve.

Conclusions:

Sous natalizumab, certains patients ont note une diminution importante du taux de recidive, une stabilisation du score a l’EDSS et une amelioration de leur QV et de leur niveau d’energie, ce qui est similaire aux effets observes dans l’etude pivot.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 3 , May 2011 , pp. 422 - 428
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4):655–61.Google Scholar
2 Johnson, KP, Brooks, BR, Cohen, JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45(7):1268–76.CrossRefGoogle ScholarPubMed
3 Jacobs, LD, Cookfair, DL, Rudick, RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285–94.Google Scholar
4 Ebers, GC, Hommes, O, Hughes, RAC, et al. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139): 1498–504.Google Scholar
5 Yednock, TA, Cannon, C, Fritz, LC, Sanchez-Madrid, F, Steinman, L, Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 1992; 356(6364):63–6.Google Scholar
6 Baron, JL, Madri, JA, Ruddle, NH, Hashim, G, Janeway, CA Jr. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993;177:57–68.CrossRefGoogle Scholar
7 Lobb, RR, Mehmler, ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94(5):1722–8Google Scholar
8 Polman, CH, O’Connor, PW, Havrdova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.Google Scholar
9 Rudick, RA, Stuart, WH, Calabresi, PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.Google Scholar
10 Rudick, RA, Miller, D, Hass, S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62 (4):335–46.Google Scholar
11 Putzki, N, Yaldizli, O, Maurer, M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2010;17(1):31–7.Google Scholar
12 Putzki, N, Kollia, K, Woods, S, Egwe, E, Diener, HC, Limmroth, V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol. 2009;16 (3):424–6.Google Scholar
13 Oturai, AB, Koch-Henriksen, N, Petersen, T, Jensen, PEH, Sellebjerg, F, Sorensen, PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16:420–3.Google Scholar
14 Outteryck, O, Ongagna, JC, Zephir, H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010;257:207–11.Google Scholar
15 Sangalli, F, Moiola, L, Bucello, S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2010. Epub 2010 June 11.Google Scholar
16 Belachew, S, Phan-Ba, R, Bartholome, E, et al. Natalizumab induced a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2010. Epub 2010 June 16.Google Scholar
17 Fernandez, V, Alvarenga, MP, Guerrero, M, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler. 2010. Epub 2010 Nov 18.Google Scholar
18 Bezabeth, S, Flowers, CM, Kortepeter, C, Avigan, M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther. 2010;31(9):1028–35.Google Scholar
19 Vellinga, MM, Castelijns, JA, Barkhof, F, Uitdehaag, BMJ, Polman, CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13): 1150–1.CrossRefGoogle ScholarPubMed
20 Miravalle, A, Jensen, R, Kinkel, P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2010. Epub 2010 Oct 11.Google Scholar
21 Borriello, G, Prosperini, L, Marinelli, F, Fubelli, F, Pozzilli, C. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler. 2010. Epub 2010 Dec 9.Google Scholar